Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr;27(5):1174-7.
doi: 10.1038/leu.2012.255. Epub 2012 Sep 3.

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report

S Goldman, L Smith, J R Anderson, S Perkins, L Harrison, M B Geyer, T G Gross, H Weinstein, S Bergeron, B Shiramizu, W Sanger, M Barth, J Zhi, M S Cairo

Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report

S Goldman et al. Leukemia. 2013 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

TGG is a consultant for Genentech/Roche, Allos Therapeutics, Pfizer Oncology and Eli Lilly. JZ is an employee of Roche. All other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Percentage of grade III/IV non-hematological toxicities during chemoimmunotherapy cycles. Rates of grade III/IV infection, mucositis and pain, by treatment cycle. In the initial subpilot, patients did not receive rituximab during the first induction cycle (COPADM1) and therefore toxicity for this cycle is shown separately. All other cycles combine subpilot (n = 7) and pilot (n = 38) data.
Figure 2
Figure 2
Probability of EFS and OS of all eligible intermediate-risk patients. (a) Product-limit estimate of probability of EFS in all pilot patients (six doses or rituximab plus chemotherapy) from study entry. EFS at 3 years (CI95% 80–99%). (b) Product-limit estimate of probability of OS in all patients from study entry. OS at 3 years (CI95% 83–99%). (c) Product-limit estimate of probability of EFS in all stage III/IV pilot patients on study compared to all stage III/IV patients treated on FAB/LMB 96 without rituximab.
See this image and copyright information in PMC

References

    1. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28:3115–3121. - PubMed
    1. Murphy SB. Classification, staging and end results of treatment of childhood non- Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7:332–339. - PubMed
    1. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–2780. - PMC - PubMed
    1. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–2743. - PMC - PubMed
    1. Shiramizu B, Goldman S, Kusao I, Agsalda M, Lynch J, Smith L, et al. Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: a children’s oncology group report. Br J Haematol. 2011;153:758–763. - PMC - PubMed

Publication types

MeSH terms

Supplementary concepts